Valneva confirms participation in UK government COVID-19 vaccine response program
Valneva has reached agreement in principle with the UK government to provide up to 100 million doses of its SARS-CoV-2 vaccine candidate.
MVM invests in MDxHealth SA
MVM closed a growth investment in MDxHealth SA, a company that markets tests that optimize the care of patients with prostate cancer.
MVM leads investment round in SkyCell
MVM led the growth investment round in SkyCell, a company that has developed patented temperature-control technology to transport vaccines and biotechnology drugs.
Valneva and Pfizer announce collaboration on Lyme Disease vaccine, VLA-15
Valneva and Pfizer announced a collaboration to develop and commercialize Valneva’s Lyme disease vaccine candidate VLA15, which is currently in Phase 2 clinical studies.
MVM Partners LLP Closes Fund V
MVM Partners announces the closing of a $325 million healthcare fund, MVM V.
HLS Therapeutics announces Health Canada approval for Vascepa® to reduce the risk of cardiovascular events
HLS Therapeutics announces that Health Canada has approved the use of Vascepa® to reduce the risk of cardiovascular events in statin-treated patients with elevated triglycerides, who are at high risk of cardiovascular events due to established cardiovascular disease, or diabetes, and at least one other cardiovascular risk factor.
Biotheranostics launches Not Another Minute campaign for its Breast Cancer Index® test
Biotheranostics announces the launch of its Not Another minute campaign, revealing how Breast Cancer Index is changing the game for early-stage, hormone receptor-positive breast cancer patients.
Vertos MOTION study enrollment complete
Vertos Medical completes enrollment in MOTION study of mild® procedure, a minimally invasive treatment for lumbar spinal stenosis
HLS Therapeutics announces Health Canada grants medical device license for CSAN PRONTO
HLS Therapeutics Inc. announces that Health Canada has granted a medical device license for the Athelas One WBC System, marketed as CSAN PRONTO, for use as a point-of-care device indicated for quantitative determination of white blood cells and neutrophil percentages in capillary or venous whole blood.
Valneva completes recruitment for phase 2 studies of its Lyme Disease vaccine candidate VLA15
Valneva has announced that it has completed patient recruitment of the Phase 2 studies for its Lyme disease vaccine candidate, VLA15.